Maekawa H

ORCID: 0000-0002-0200-414X · 1 paper in corpus · active 2025
2025
International cancer conference journal ·doi:10.1007/s13691-024-00739-6

The combination therapy of lenvatinib plus pembrolizumab (LP) is increasingly recognized as an important second-line regimen for advanced or recurrent endometrial cancer (EC). However, the safety and efficacy of conversion surgery with low …